1
|
Coetzee LM, Cassim N, Glencross DK. Newly implemented community CD4 service in Tshwaragano, Northern Cape province, South Africa, positively impacts result turn-around time. Afr J Lab Med 2022; 11:1376. [PMID: 35811752 PMCID: PMC9257740 DOI: 10.4102/ajlm.v11i1.1376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Accepted: 02/25/2022] [Indexed: 11/17/2022] Open
Abstract
Background The Northern Cape is South Africa’s largest province with an HIV prevalence of 7.1% versus a 13.5% national prevalence. CD4 testing is provided at three of five National Health Laboratory Service district laboratories, each covering a 250 km precinct radius. Districts without a local service report prolonged CD4 turn-around times (TAT). Objective This study documented the impact of a new CD4 laboratory in Tshwaragano in the remote John Taolo Gaetsewe district of the Northern Cape, South Africa. Methods CD4 test volumes and TAT (total, pre-analytical, analytical, and post-analytical) data for the Northern Cape province were extracted for June 2018 to October 2019. The percentage of CD4 results within the stipulated 40-h TAT cut-off and the median and 75th percentiles of all TAT parameters were calculated. Pre-implementation, samples collected at Tshwaragano were referred to Kimberley or Upington, Northern Cape, South Africa. Results Pre-implementation, 95.4% of samples at Tshwaragano were referred to Kimberley for CD4 testing (36.3% of Kimberley’s test volumes). Only 7.5% of Tshwaragano’s total samples were referred post-implementation. The Tshwaragano laboratory’s CD4 median total TAT decreased from 24.7 h pre-implementation to 12 h post-implementation (p = 0.003), with > 95.0% of results reported within 40 h. The Kimberley laboratory workload decreased by 29.0%, and testing time significantly decreased from 10 h to 4.3 h. Conclusion The new Tshwaragano CD4 service significantly decreased local TAT. Upgrading existing community laboratories to include CD4 testing can alleviate provincial service load and improve local access, TAT and efficiency in the centralised reference laboratory.
Collapse
Affiliation(s)
- Lindi-Marie Coetzee
- National Priority Programme, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa
| | - Naseem Cassim
- National Priority Programme, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa
| | - Deborah K. Glencross
- National Priority Programme, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
2
|
OUP accepted manuscript. Lab Med 2022; 53:614-618. [DOI: 10.1093/labmed/lmac037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Perazzio SF, Palmeira P, Moraes-Vasconcelos D, Rangel-Santos A, de Oliveira JB, Andrade LEC, Carneiro-Sampaio M. A Critical Review on the Standardization and Quality Assessment of Nonfunctional Laboratory Tests Frequently Used to Identify Inborn Errors of Immunity. Front Immunol 2021; 12:721289. [PMID: 34858394 PMCID: PMC8630704 DOI: 10.3389/fimmu.2021.721289] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2021] [Accepted: 10/05/2021] [Indexed: 12/24/2022] Open
Abstract
Inborn errors of immunity (IEI), which were previously termed primary immunodeficiency diseases, represent a large and growing heterogeneous group of diseases that are mostly monogenic. In addition to increased susceptibility to infections, other clinical phenotypes have recently been associated with IEI, such as autoimmune disorders, severe allergies, autoinflammatory disorders, benign lymphoproliferative diseases, and malignant manifestations. The IUIS 2019 classification comprises 430 distinct defects that, although rare individually, represent a group affecting a significant number of patients, with an overall prevalence of 1:1,200-2,000 in the general population. Early IEI diagnosis is critical for appropriate therapy and genetic counseling, however, this process is deeply dependent on accurate laboratory tests. Despite the striking importance of laboratory data for clinical immunologists, several IEI-relevant immunoassays still lack standardization, including standardized protocols, reference materials, and external quality assessment programs. Moreover, well-established reference values mostly remain to be determined, especially for early ages, when the most severe conditions manifest and diagnosis is critical for patient survival. In this article, we intend to approach the issue of standardization and quality control of the nonfunctional diagnostic tests used for IEI, focusing on those frequently utilized in clinical practice. Herein, we will focus on discussing the issues of nonfunctional immunoassays (flow cytometry, enzyme-linked immunosorbent assays, and turbidimetry/nephelometry, among others), as defined by the pure quantification of proteins or cell subsets without cell activation or cell culture-based methods.
Collapse
Affiliation(s)
- Sandro Félix Perazzio
- Division of Rheumatology, Universidade Federal de São Paulo, Sao Paulo, Brazil.,Immunology Division, Fleury Medicine and Health Laboratory, Sao Paulo, Brazil
| | - Patricia Palmeira
- Laboratório de Investigação Médica (LIM-36), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil
| | - Dewton Moraes-Vasconcelos
- Laboratório de Investigação Médica (LIM-56), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil
| | - Andréia Rangel-Santos
- Laboratório de Investigação Médica (LIM-36), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil
| | | | - Luis Eduardo Coelho Andrade
- Division of Rheumatology, Universidade Federal de São Paulo, Sao Paulo, Brazil.,Immunology Division, Fleury Medicine and Health Laboratory, Sao Paulo, Brazil
| | - Magda Carneiro-Sampaio
- Laboratório de Investigação Médica (LIM-36), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil.,Department of Pediatrics, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil
| |
Collapse
|
4
|
Evaluation of a collaborative model for successful implementation of a National CD4 enumeration EQA program in Cameroon. Sci Rep 2021; 11:11536. [PMID: 34078982 PMCID: PMC8172912 DOI: 10.1038/s41598-021-91015-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 05/17/2021] [Indexed: 11/12/2022] Open
Abstract
Participation in an EQA program is critical to the quality assurance process. Reliable and precise CD4 T-cells enumeration are essential to improve the clinical management of patients by evaluating the disease progression and by monitoring the effectiveness of ART in HIV-patients. The CIRCB, CD4 reference laboratory, in collaboration with the Canadian QASI-program, recruited sites, distributed and analyzed CD4-panels in 61 sites across Cameroon. A trend and performance analysis in the pre-analytical, analytical and post-analytical phases was performed. Continuous training and corrective actions carried out from 2014 to 2018 increased the number of participating sites from 15 to 61 sites, the number of unacceptable results decreased from 50 to 10%. Specific challenges included errors in pre analytic (17.5%), analytic (77.0%) and post-analytic (5.5%) phases. This EQA requires the application of good laboratory practices, fluidic communication between all the stakeholders, continuous training, application of specific on-site corrective measures, and timely equipment maintenance in order to avoid repetitive errors and to increase laboratory performance. It could be extended to other HIV-1 testing like viral load and EID point-of-care. Partnership with QASI serve as a model for implementation of a successful EQA model for resource limited countries wanting to implement EQA for HIV testing and monitoring in alignment with 90–90–90 targets.
Collapse
|
5
|
Chambuso R, Ramesar R, Kaambo E, Murahwa AT, Abdallah MO, De Sousa M, Denny L, Williamson AL, Gray CM. Age, absolute CD4 count, and CD4 percentage in relation to HPV infection and the stage of cervical disease in HIV-1-positive women. Medicine (Baltimore) 2020; 99:e19273. [PMID: 32118737 PMCID: PMC7478573 DOI: 10.1097/md.0000000000019273] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
A subgroup of women who are co-infected with human immunodeficiency virus type 1 (HIV-1) and human papillomavirus (HPV), progress rapidly to cervical disease. We characterized HPV genotypes within cervical tumor biopsies, assessed the relationships of cervical disease stage with age, HIV-1 status, absolute CD4 count, and CD4 percentage, and identified the predictive power of these variables for cervical disease stage in a cohort of South African women.We recruited 181 women who were histologically diagnosed with cervical disease; 87 were HIV-1-positive and 94 were HIV-1-seronegative. Colposcopy-directed tumor biopsies were confirmed by histology and used for genomic DNA extraction. The Roche Linear Array HPV genotyping test was used for HPV genotyping. Peripheral whole blood was used for HIV-1 rapid testing. Fully automated FC500MPL/CellMek with PanLeucogate (PLG) was used to determine absolute CD4 count, CD4 percentage, and CD45 count. Chi-squared test, a logistic regression model, parametric Pearson correlation, and ROC curves were used for statistical analyses. We used the Benjamini-Horchberg test to control for false discovery rate (FDR, q-value). All tests were significant when both P and q were <.05.Age was a significant predictor for invasive cervical cancer (ICC) in both HIV-1-seronegative (P < .0001, q < 0.0001) and HIV-1-positive women (P = .0003, q = 0.0003). Sixty eight percent (59/87) of HIV-1-positive women with different stages of cervical disease presented with a CD4 percentage equal or less than 28%, and a median absolute CD4 count of 400 cells/μl (IQR 300-500 cells/μl). Of the HIV-1-positive women, 75% (30/40) with ICC, possessed ≤28% CD4 cells vs 25% (10/40) who possessed >28% CD4 cells (both P < .001, q < 0.001). Furthermore, 70% (28/40) of women with ICC possessed CD4 count >350 compared to 30% (12/40) who possessed CD4 count ≤ 350 (both P < .001, q < 0.001).Age is an independent predictor for ICC. In turn, development of ICC in HIV-1-positive women is independent of the host CD4 cells and associates with low CD4 percentage regardless of absolute CD4 count that falls within the normal range. Thus, using CD4 percentage may add a better prognostic indicator of cervical disease stage than absolute CD4 count alone.
Collapse
Affiliation(s)
- Ramadhani Chambuso
- MRC Unit for Genomic and Precision Medicine, Division of Human Genetics, Department of Pathology
- Department of Gynaecology, Morogoro Regional Referral Hospital, Morogoro, Tanzania
| | - Raj Ramesar
- MRC Unit for Genomic and Precision Medicine, Division of Human Genetics, Department of Pathology
- Division of Human Genetics
| | - Evelyn Kaambo
- Division of Medical Virology, Department of Pathology, Faculty of Health Sciences
- Department of Biochemistry and Medical Microbiology, University of Namibia School of Medicine, Windhoek, Namibia
| | | | - Mohammed O.E. Abdallah
- MRC Unit for Genomic and Precision Medicine, Division of Human Genetics, Department of Pathology
- Department of Gynaecology, Morogoro Regional Referral Hospital, Morogoro, Tanzania
| | - Michelle De Sousa
- Department of Obstetrics and Gynaecology, Victoria Wynberg Hospital, Cape Town
- South African Medical Research Council, Clinical Gynaecological Cancer Research Centre
| | - Lynette Denny
- South African Medical Research Council, Clinical Gynaecological Cancer Research Centre
- Department of Obstetrics and Gynaecology
| | - Anna-Lise Williamson
- Division of Medical Virology, Department of Pathology, Faculty of Health Sciences
- South African Medical Research Council, Clinical Gynaecological Cancer Research Centre
| | - Clive M. Gray
- Division of Immunology, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town
- National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa
| |
Collapse
|
6
|
Yibalih NK, Wolday D, Kinde S, Weldearegay GM. External Quality Assessment on CD4+ T-Cell Count Using in-House Proficiency Testing Panels for CD4 Count Laboratories in Addis Ababa, Ethiopia. Ethiop J Health Sci 2020; 29:309-320. [PMID: 31447499 PMCID: PMC6689725 DOI: 10.4314/ejhs.v29i3.3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background CD4+ T-cell count External Quality Assessment program is important for the evaluation of performance of CD4 count laboratories. The aim of this study was to assess the quality of CD4count laboratory performance using in-house Proficiency testing panels that perform routine CD4 counts in Addis Ababa, Ethiopia, 2013/14. Methods Participating laboratories were 20, 23 and 25 in trials 1, 2 and 3, respectively. In-house prepared fresh whole blood samples both with “normal” and “low” CD4 values were sent to participating laboratories. Percentage and absolute counts of CD4+ T-lymphocytes were done using their routine procedures. Data were analyzed for each trial including trimmed mean, standard deviation (SD), percent coefficient of variation (%CV), residual, and standard deviation index (SDI) values for both absolute counts and percentages of CD4+ lymphocytes (%CD4). Results Most participating laboratories produced results that were within 2SD of the mean. Average inter-laboratory precision (trimmed %CV) was 10.87% and 5.14% for CD4 absolute counts and %CD4, respectively. For normal material, the trimmed mean %CV was 9.59% and3.23% for CD4 absolute counts and %CD4, respectively. For low material, the trimmed mean % CV was 12.15% and 7.05% for CD4 absolute counts and %CD4 respectively. BDFACSCount™ users showed the best accuracy and precision as evidenced by longitudinal analysis. Conclusion This study was found to help facilities in early identifying their gaps with regard to their CD4 count performance and in avoiding the challenges encountered during participation in external EQA providers like the high cost, transportation problem, feedback delay and CD4laboratory coverage.
Collapse
Affiliation(s)
- Natnael Kidanu Yibalih
- School of Medicine, Aksum University, College of Health Science and Comprehensive Specialized Hospital, Aksum, Ethiopia
| | - Dawit Wolday
- Manager of Medical Biotech Laboratory, Addis Ababa, Ethiopia
| | - Samuel Kinde
- Department of Medical Laboratory Science, Addis Ababa University, Addis Ababa, Ethiopia
| | | |
Collapse
|
7
|
Payne H, Lawrie D, Nieuwoudt M, Cotton MF, Gibb DM, Babiker A, Glencross D, Klein N. Comparison of Lymphocyte Subset Populations in Children From South Africa, US and Europe. Front Pediatr 2020; 8:406. [PMID: 32793531 PMCID: PMC7390891 DOI: 10.3389/fped.2020.00406] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Accepted: 06/12/2020] [Indexed: 11/13/2022] Open
Abstract
Background: Typically, African healthcare providers use immunological reference intervals adopted from Europe and the United States (US). This may be inappropriate in a setting with many differences including exposure to different environmental stimuli and pathogens. We compared immunological reference intervals for children from Europe and the US with South African children to explore whether healthy children living in settings with high rates of infectious diseases have different baseline immunological parameters. Methodology: Blood was taken from 381 HIV-uninfected children aged between 2 weeks and 13 years of age from a Child Wellness Clinic in an informal settlement in Cape Town to establish local hematological and lymphocyte reference intervals for South African children. Flow-cytometry quantified percentage and absolute counts of the B-cells, NK-cells, and T-cells including activated, naïve, and memory subsets. These parameters were compared to three separate studies of healthy children in Europe and the US. Results: Increased activated T-cells, and natural killer cells were seen in the younger age-groups. The main finding across all age-groups was that the ratio of naïve/memory CD4 and CD8 T-cells reached a 1:1 ratio around the first decade of life in healthy South African children, far earlier than in resource-rich countries, where it occurs around the fourth decade of life. Conclusions: This is the largest data set to date describing healthy children from an African environment. These data have been used to create local reference intervals for South African children. The dramatic decline in the naïve/memory ratio of both CD4 and CD8 T-cells alongside increased activation markers may indicate that South African children are exposed to a wider range of environmental pathogens in early life than in resource-rich countries. These marked differences illustrate that reference intervals should be relevant to the population they serve. The implications for the developing pediatric immune system requires further investigation.
Collapse
Affiliation(s)
- Helen Payne
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Denise Lawrie
- National Health Laboratory Service, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa
| | - Martin Nieuwoudt
- Institute for Biomedical Engineering (IBE), Stellenbosch University, Stellenbosch, South Africa
| | - Mark Fredric Cotton
- Family Centre for Research With Ubuntu, Stellenbosch University, Cape Town, South Africa
| | - Diana M Gibb
- Clinical Trials Unit, Medical Research Council, London, United Kingdom
| | - Abdel Babiker
- Clinical Trials Unit, Medical Research Council, London, United Kingdom
| | - Debbie Glencross
- National Health Laboratory Service, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa
| | - Nigel Klein
- UCL Great Ormond Street Institute of Child Health, London, United Kingdom
| |
Collapse
|
8
|
Rhodes D, Carcelain G, Keeney M, Parizot C, Benjamins D, Genesta L, Zhang J, Rohrbach J, Lawrie D, Glencross DK. Assessment of the AQUIOS flow cytometer - An automated sample preparation system for CD4 lymphocyte PanLeucogating enumeration. Afr J Lab Med 2019; 8:804. [PMID: 31850159 PMCID: PMC6909423 DOI: 10.4102/ajlm.v8i1.804] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Accepted: 03/18/2019] [Indexed: 11/16/2022] Open
Abstract
Background Flow cytometry has been the approach of choice for enumerating and documenting CD4-cell decline in HIV monitoring. Beckman Coulter has developed a single platform test for CD4+ T-cell lymphocyte count and percentage using PanLeucogating (PLG) technology on the automated AQUIOS flow cytometer (AQUIOS PLG). Objectives This study compared the performance of AQUIOS PLG with the Flowcare PLG method and performed a reference interval for comparison with those previously published. Methods The study was conducted between November 2014 and March 2015 at 5 different centres located in Canada; Paris, France; Lyon, France; the United States; and South Africa. Two-hundred and forty samples from HIV-positive adult and paediatric patients were used to compare the performances of AQUIOS PLG and Flowcare PLG on a FC500 flow cytometer (Flowcare PLG) in determining CD4+ absolute count and percentage. A reference interval was determined using 155 samples from healthy, non-HIV adults. Workflow was investigated testing 440 samples over 5 days. Results Mean absolute and relative count bias between AQUIOS PLG and Flowcare PLG was −41 cells/µL and −7.8%. Upward and downward misclassification at various CD4 thresholds was ≤ 2.4% and ≤ 11.1%. The 95% reference interval (2.5th – 97.5th) for the CD4+ count was 453–1534 cells/µL and the percentage was 30.5% – 63.4%. The workflow showed an average number of HIV samples tested as 17.5 per hour or 122.5 per 8-hour shift for one technician, including passing quality controls. Conclusion The AQUIOS PLG merges desirable aspects from conventional flow cytometer systems (high throughput, precision and accuracy, external quality assessment compatibility) with low technical operating skill requirements for automated, single platform systems.
Collapse
Affiliation(s)
- Daniel Rhodes
- Clinical Affairs, Beckman Coulter Immunotech, Marseille, France
| | | | - Mike Keeney
- Lawson Health Research Institute, London Health Sciences Centre and St. Joseph's Health Care, Victoria Hospital, London, Ontario, Canada
| | | | | | | | - Jin Zhang
- Life Science Flow Cytometry, Beckman Coulter Incorporated, Miami, Florida, United States
| | - Justin Rohrbach
- Clinical affairs, Beckman Coulter Incorporated, Miami, Florida, United States
| | - Denise Lawrie
- National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
| | - Deborah K Glencross
- Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.,National Health Laboratory Services, Johannesburg, South Africa
| |
Collapse
|
9
|
Glencross DK, Coetzee LM. Categorizing and Establishing CD4 Service Equivalency: Testing of Residual, Archived External Quality Assessment Scheme Sample Panels Enables Accelerated Virtual Peer Laboratory Review. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019; 96:404-416. [PMID: 30821061 DOI: 10.1002/cyto.b.21772] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Revised: 01/18/2019] [Accepted: 01/23/2019] [Indexed: 11/09/2022]
Abstract
BACKGROUND Testing of collated, curated residual archived external quality assessment (EQA) trial material, with pre-established true (consensus) values collated into 25-sample panels enables virtual peer review of a laboratory's proficiency. In this study, we introduce how archived EQAS samples/panels can establish equivalency of CD4 reporting across multiple laboratories in a national program. METHODS Curated unused trial material from archived EQAS CD4 trials were collated into 25-sample panels comprising three sets of five-sample replicates and at least three duplicate samples. Panel-samples were tested using predicate methods of participating laboratories and proficiency determined by calculating a Standard Deviation Index (SDI) for each panel-sample reported according to retrospective consensus pooled trial outcomes. All data were plotted using MS Excel and Graphpad-Prism with SDI limits between -2 and +2 SDI to define acceptable performance. Percentage similarity analysis determined agreement. Bead-count-rate data was used to determine pipetting error. RESULTS Tight clustering of SDI outcomes predicted acceptable laboratory proficiency with acceptable accuracy and precision as evidenced by mean SDI < 0.5 and SD of SDI < 0.5. Random pipetting error was identified with aberrant BCR. Systematic under-reading of results was noted in one lab with excellent precision but mean SDI > 1.6. Additional training requirements were evident where a respective laboratory's SD of SDI exceeded 0.7. CONCLUSIONS Archival panel testing undertaken across a network of CD4 laboratories using the same CD4 method to simultaneously test the same panel prior to national implementation highlighted proficient laboratories and was useful for identifying sites with service deficiencies and immediate additional training needs. © 2019 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Deborah Kim Glencross
- National Health Laboratory Service (NHLS), National Priority Programme, Johannesburg, South Africa.,Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
| | - Lindi Marie Coetzee
- National Health Laboratory Service (NHLS), National Priority Programme, Johannesburg, South Africa.,Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
10
|
Aggett H, Dabula P, Mayne ES, Louw S. A pilot study to introduce a local external quality assurance scheme for D-dimers in the National Health Laboratory Service, in South Africa. Int J Lab Hematol 2019; 41:298-303. [PMID: 30689284 DOI: 10.1111/ijlh.12973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Revised: 11/30/2018] [Accepted: 12/12/2018] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Laboratory quality assurance (QA) includes internal quality control (IQC), external quality assurance (EQA) and quality improvement (QI). EQA identifies quality deviations and training needs. D-dimers are breakdown products of thrombus and results guide various clinical decisions. METHODS The National Health Laboratory Service (NHLS) in South Africa performs the pathology tests for more than 80% of the population. The NHLS Quality Assurance Department distributed 301 questionnaires to laboratories enquiring about D-dimer testing. Two levels of STAGO® and Siemens® commercial D-dimer assay control material were distributed for analysis and returned results analysed. RESULTS A total of 64 (21.2%) completed questionnaires were returned and 26 (40.6%) laboratories were performing D-dimers with 25 (97%) subscribing to an EQA scheme. All laboratories reported results in D-dimer units with a negative result cut-off of ≤0.25 mg/L but various testing platforms were in use. All returned interpretations of analyses on the blinded control material were correct. The results were also within the respective reference ranges of the controls apart from three outliers. One laboratory obtained a result on STAGO® pathological control that was above the cut-off of the control reference range but the reason for this error could not be identified. Another obtained results on the STAGO® and on the Siemens® normal controls that were both below the cut-off of the control reference range due to transcription errors. CONCLUSION The study demonstrated the feasibility of a local EQA scheme for D-dimers based on commercial control material that could mitigate against the cost of international EQA scheme participation.
Collapse
Affiliation(s)
- Hazel Aggett
- National Health Laboratory Service (NHLS), Department of Molecular Medicine and Haematology, University of the Witwatersrand (WITS), Johannesburg, South Africa
| | - Patience Dabula
- National Health Laboratory Service (NHLS), Department of Molecular Medicine and Haematology, University of the Witwatersrand (WITS), Johannesburg, South Africa
| | - Elizabeth S Mayne
- National Health Laboratory Service (NHLS), Department of Molecular Medicine and Haematology, University of the Witwatersrand (WITS), Johannesburg, South Africa
| | - Susan Louw
- National Health Laboratory Service (NHLS), Department of Molecular Medicine and Haematology, University of the Witwatersrand (WITS), Johannesburg, South Africa
| |
Collapse
|
11
|
Cassim N, Coetzee LM, Stevens WS, Glencross DK. Addressing antiretroviral therapy-related diagnostic coverage gaps across South Africa using a programmatic approach. Afr J Lab Med 2018; 7:681. [PMID: 30473993 PMCID: PMC6244076 DOI: 10.4102/ajlm.v7i1.681] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 05/02/2018] [Indexed: 11/17/2022] Open
Abstract
Background A major challenge facing South Africa is the concomitant HIV and tuberculosis epidemics. The National Health Laboratory Service provides testing for staging HIV-positive patients, monitoring patients on antiretroviral therapy (ART) and diagnosing tuberculosis. Not all health districts have equivalent ART-related coverage in particular for CD4 and HIV viral load testing. Objectives The Integrated Tiered Service Delivery Model coverage precinct approach was used to address ART-related testing service coverage gaps in a manner that balances cost, quality and equity. Methods An algorithm was developed to identify and address ART-related diagnostic coverage gaps. Data was extracted from the corporate data warehouse and Oracle systems for the period of April 2015 to March 2016. Daily test volumes were based on 21.73 working days per month. Data were analysed using MS Excel and mapped using ArcCatalog and ArcMap. Capacity analysis was informed by the available testing-platforms. Results Health district daily HIV viral load volumes ranged from 2 to 1308 samples. Nineteen candidate laboratories were identified to address the coverage gaps. Following the proximity analysis, testing was consolidated at four candidate laboratories, resulting in 13 revised candidate laboratories. The revised candidate laboratory daily HIV viral load referrals ranged between 5 and 205 samples, with CD4 volumes between 6 and 85 samples. Remaining coverage gaps were identified in seven municipalities. Conclusions The study demonstrated that the service coverage precinct approach could be used to identify coverage gaps for a defined ART-related testing repertoire.
Collapse
Affiliation(s)
- Naseem Cassim
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.,National Priority Programme, National Health Laboratory Service, Johannesburg, South Africa
| | - Lindi M Coetzee
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.,National Priority Programme, National Health Laboratory Service, Johannesburg, South Africa
| | - Wendy S Stevens
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.,National Priority Programme, National Health Laboratory Service, Johannesburg, South Africa
| | - Deborah K Glencross
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.,National Priority Programme, National Health Laboratory Service, Johannesburg, South Africa
| |
Collapse
|
12
|
Daniel Francois Venter W, Chersich MF, Majam M, Akpomiemie G, Arulappan N, Moorhouse M, Mashabane N, Glencross DK. CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values? Int J STD AIDS 2018; 29:1048-1056. [PMID: 29749876 DOI: 10.1177/0956462418771768] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Although eligibility for antiretroviral treatment is no longer based on CD4 thresholds, CD4 testing remains important. Variation in CD4 cell count complicates initiation of antibiotic prophylaxis, differential diagnoses and assessments of immunological recovery. Five hundred and fifty-three HIV-positive antiretroviral-naïve adults, recruited from inner-city clinics, had three serial CD4 cell count tests. Test 1 was mostly done in a laboratory network supporting primary care clinics, while Tests 2 and 3 were performed in a tertiary-level laboratory. Reproducibility was assessed through Bland-Altman limits of agreement and coefficients of variation. Participants, a mean age of 34 years and mostly female (57%), had a median 203 CD4 cells/μL (Test 1). Seventeen per cent classified as having advanced HIV disease (CD4 cell count < 200 cells/µL) on Test 1 had a CD4 cell count > 200 cells/µL on Tests 2 and 3. Mean differences between tests were <10 cells/µL for all comparisons. Limits of agreement for Tests 1 and 2 were -106.9 to 112.7 and coefficient of variation 15. Corresponding figures for Tests 2 and 3 were -88.2 to 103.4, and 13. Means of tests were similar, suggesting no systematic measurement differences, despite testing being done at different times. Variations were, however, considerable in many instances, though smaller in testing done in the same laboratory. CD4 cut-offs must not be applied rigidly, but rather constitute one amongst many factors used to guide patient care. Moreover, given the difficulties in determining whether CD4 changes are due to HIV disease, or other biological and laboratory factors, CD4 laboratory reports should include a range of plausible values, not only the absolute count.
Collapse
Affiliation(s)
- Willem Daniel Francois Venter
- 1 Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg, South Africa
| | - Matthew F Chersich
- 1 Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg, South Africa
| | - Mohammed Majam
- 1 Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg, South Africa
| | - Godspower Akpomiemie
- 1 Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg, South Africa
| | - Natasha Arulappan
- 1 Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg, South Africa
| | - Michelle Moorhouse
- 1 Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg, South Africa
| | - Nonkululeko Mashabane
- 1 Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg, South Africa
| | - Deborah K Glencross
- 2 Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa
| |
Collapse
|
13
|
Gaspar PC, Wohlke BLP, Brunialti MKC, Pires AF, Kohiyama IM, Salomão R, Alonso Neto JB, Júnior ODCF, Franchini M, Bazzo ML, Benzaken AS. External quality assessment for CD4 + T-lymphocyte count test: Performance of the Brazilian public health laboratories network. Medicine (Baltimore) 2018; 97:S32-S37. [PMID: 29794603 PMCID: PMC5991543 DOI: 10.1097/md.0000000000010125] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The National Network for CD4+ T-lymphocyte counting of Brazil comprises 93 laboratories. This study reports the laboratory performances achieved in external quality assessment (EQA) rounds provides by Ministry of Health to evaluate the quality of the kits used and the performance of test by the technicians.Ten EQA rounds were analyzed according the EQA criteria aimed to evaluate individual laboratory performance on the basis of the accuracy of their results compared to the general mean obtained by all participating laboratories and the reproducibility of the results obtained between 2 samples from the same donor.The percentage of approved and failed laboratories in the EQAs tends to follow a uniform pattern. Since 2011, approval has remained above 80% and the failure rate has never exceeded 15%.EQA is very important to evaluate the performance of the laboratories, to identify monitor, and to resolve errors as quickly as possible.
Collapse
Affiliation(s)
- Pâmela Cristina Gaspar
- Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis (DIAHV), Secretariat of Health Surveillance, Ministry of Health, Brasília, Distrito Federal
| | - Bruna Lovizutto Protti Wohlke
- Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis (DIAHV), Secretariat of Health Surveillance, Ministry of Health, Brasília, Distrito Federal
| | - Milena Karina Coló Brunialti
- Immunology Laboratory/Division of Infectious Diseases/Escola Paulista de Medicina/Federal University of São Paulo, São Paulo
| | - Ana Flávia Pires
- Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis (DIAHV), Secretariat of Health Surveillance, Ministry of Health, Brasília, Distrito Federal
| | - Igor Massaki Kohiyama
- Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis (DIAHV), Secretariat of Health Surveillance, Ministry of Health, Brasília, Distrito Federal
| | - Reinaldo Salomão
- Immunology Laboratory/Division of Infectious Diseases/Escola Paulista de Medicina/Federal University of São Paulo, São Paulo
| | - José Boullosa Alonso Neto
- Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis (DIAHV), Secretariat of Health Surveillance, Ministry of Health, Brasília, Distrito Federal
| | | | - Miriam Franchini
- Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis (DIAHV), Secretariat of Health Surveillance, Ministry of Health, Brasília, Distrito Federal
| | - Maria Luiza Bazzo
- Laboratory of Molecular Biology, Microbiology and Serology, Department of Clinical Analysis, Health Sciences Center, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil
| | - Adele Schwartz Benzaken
- Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis (DIAHV), Secretariat of Health Surveillance, Ministry of Health, Brasília, Distrito Federal
| |
Collapse
|
14
|
Coetzee LM, Glencross DK. Performance verification of the new fully automated Aquios flow cytometer PanLeucogate (PLG) platform for CD4-T-lymphocyte enumeration in South Africa. PLoS One 2017; 12:e0187456. [PMID: 29099874 PMCID: PMC5669480 DOI: 10.1371/journal.pone.0187456] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 10/22/2017] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND The National Health Laboratory Service (NHLS) offers wide-scale CD4 testing through a network of laboratories in South Africa. A new "load and go" cytometer (Aquios CL, Beckman Coulter), developed with a PLG protocol, was validated against the predicate PLG method on the Beckman Coulter FC500 MPL/CellMek platform. METHODS Remnant routine EDTA blood CD4 reference results were compared to results from two Aquios/PLG instruments (n = 205) and a further n = 1885 samples tested to assess daily testing capacity. Reproducibility was assessed using ImmunotrolTM and patient samples with low, medium, high CD4 counts. Data was analyzed using GraphPad software for general statistics and Bland-Altman (BA) analyses. The percentage similarity (%Sim) was used to measure the level of agreement (accuracy) of the new platform versus the predicate and variance (%SimCV) reported to indicate precision of difference to predicate. RESULTS 205 samples were tested with a CD4 count range of 2-1228 cells/μl (median 365cells/μl). BA analysis revealed an overall -40.5±44.0cells/μl bias (LOA of 126.8 to 45.8cells/μl) and %Sim showing good agreement and tight precision to predicate results (94.83±5.39% with %SimCV = 5.69%). Workflow analysis (n = 1885) showed similar outcomes 94.9±8.9% (CV of 9.4%) and 120 samples/day capacity. Excellent intra-instrument reproducibility was noted (%Sim 98.7±2.8% and %SimCV of 2.8%). 5-day reproducibility using internal quality control material (Immunotrol™) showed tight precision (reported %CV of 4.69 and 7.62 for Normal and Low material respectively) and instrument stability. CONCLUSION The Aquios/PLG CD4 testing platform showed clinically acceptable result reporting to existing predicate results, with good system stability and reproducibility with a slight negative but precise bias. This system can replace the faded XL cytometers in low- to medium volume CD4 testing laboratories, using the standardized testing protocol, with better staff utilization especially where technical skills are lacking. Central monitoring of on-board quality assessment data facilitates proactive maintenance and networked instrument performance monitoring.
Collapse
Affiliation(s)
- Lindi-Marie Coetzee
- Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- National Health Laboratory Service (NHLS), CD4 Unit, Charlotte Maxeke Hospital, Johannesburg, South Africa
- * E-mail:
| | - Deborah K. Glencross
- Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- National Health Laboratory Service (NHLS), CD4 Unit, Charlotte Maxeke Hospital, Johannesburg, South Africa
| |
Collapse
|
15
|
Scott LE, Kestens L, Pattanapanyasat K, Sukapirom K, Stevens WS. Choosing a new CD4 technology: Can statistical method comparison tools influence the decision? CYTOMETRY PART B-CLINICAL CYTOMETRY 2017; 92:465-475. [PMID: 28296063 DOI: 10.1002/cyto.b.21522] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 12/19/2016] [Accepted: 03/06/2017] [Indexed: 11/06/2022]
Abstract
BACKGROUND Method comparison tools are used to determine the accuracy, precision, agreement, and clinical relevance of a new or improved technology versus a reference technology. Guidelines for the most appropriate method comparison tools as well as their acceptable limits are lacking and not standardized for CD4 counting technologies. METHODS Different method comparison tools were applied to a previously published CD4 dataset (n = 150 data pairs) evaluating five different CD4 counting technologies (TruCOUNT, Dual Platform, FACSCount, Easy CD4, CyFlow) on a single specimen. Bland-Altman, percentage similarity, percent difference, concordance correlation, sensitivity, specificity and misclassification method comparison tools were applied as well as visualization of agreement with Passing Bablock and Bland-Altman scatter plots. RESULTS The FACSCount (median CD4 = 245 cells/µl) was considered the reference for method comparison. An algorithm was developed using best practices of the most applicable method comparison tools, and together with a modified heat map was found useful for method comparison of CD4 qualitative and quantitative results. The algorithm applied the concordance correlation for overall accuracy and precision, then standard deviation of the absolute bias and percentage similarity coefficient of variation to identify agreement, and lastly sensitivity and misclassification rates for clinical relevance. CONCLUSION Combining method comparison tools is more useful in evaluating CD4 technologies compared to a reference CD4. This algorithm should be further validated using CD4 external quality assessment data and studies with larger sample sizes. © 2017 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Lesley E Scott
- Department of Molecular Medicine and Haematology, Faculty of Health Science, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
| | - Luc Kestens
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium and Laboratory of Immunology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - Kovit Pattanapanyasat
- Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Emerging and Neglected Infectious Diseases, Mahidol University, Nakhon Pathom, Thailand
| | - Kasma Sukapirom
- Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Emerging and Neglected Infectious Diseases, Mahidol University, Nakhon Pathom, Thailand
| | - Wendy S Stevens
- Department of Molecular Medicine and Haematology, Faculty of Health Science, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.,Department of Molecular Medicine and Haematology, The National Health Laboratory Service, Johannesburg, South Africa
| |
Collapse
|
16
|
Bainbridge J, Rountree W, Louzao R, Wong J, Whitby L, Denny TN, Barnett D. Laboratory Accuracy Improvement in the UK NEQAS Leucocyte Immunophenotyping Immune Monitoring Program: An Eleven-Year Review via Longitudinal Mixed Effects Modeling. CYTOMETRY PART B-CLINICAL CYTOMETRY 2017; 94:250-256. [PMID: 28480599 DOI: 10.1002/cyto.b.21531] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 04/11/2017] [Accepted: 05/01/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND The United Kingdom National External Quality Assessment Service (UK NEQAS) for Leucocyte Immunophenotyping Immune Monitoring Programme, provides external quality assessment (EQA) to non-U.S. laboratories affiliated with the NIH NIAID Division of AIDS (DAIDS) clinical trials networks. Selected laboratories are required to have oversight, performance monitoring, and remediation undertaken by Immunology Quality Assessment (IQA) staff under the DAIDS contract. We examined whether laboratory accuracy improves with longer EQA participation and whether IQA remediation is effective. METHODS Laboratory accuracy, defined by the measurement residuals from trial sample medians, was measured on four outcomes: both CD4+ absolute counts (cells/μL) and percentages; and CD8+ absolute counts (cells/μL) and percentages. Three laboratory categories were defined: IQA monitored (n = 116), United Kingdom/non-DAIDS (n = 137), and non-DAIDS/non-UK (n = 1034). For absolute count outcomes, the groups were subdivided into single platform and dual platform users. RESULTS Increasing EQA duration was found to be associated with increasing accuracy for all groups in all four lymphocyte subsets (P < 0.0001). In the percentage outcomes, the typical IQA group laboratory improved faster than laboratories from the other two groups (P < 0.005). No difference in the overall rate of improvement was found between groups for absolute count outcomes. However, in the DPT subgroup the IQA group ultimately showed greater homogeneity. CONCLUSIONS EQA participation coupled with effective laboratory monitoring and remedial action is strongly associated with improved laboratory accuracy, both incrementally and in the proportion of laboratories meeting suggested standards. Improvement in accuracy provides more reliable laboratory information facilitating more appropriate patient treatment decisions. © 2017 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- John Bainbridge
- Duke Human Vaccine Institute, Duke University, Durham, North Carolina
| | - Wes Rountree
- Duke Human Vaccine Institute, Duke University, Durham, North Carolina
| | - Raul Louzao
- Duke Human Vaccine Institute, Duke University, Durham, North Carolina
| | - John Wong
- Duke Human Vaccine Institute, Duke University, Durham, North Carolina
| | - Liam Whitby
- UK NEQAS for Leucocyte Immunophenotyping, Sheffield, UK
| | - Thomas N Denny
- Duke Human Vaccine Institute, Duke University, Durham, North Carolina
| | - David Barnett
- UK NEQAS for Leucocyte Immunophenotyping, Sheffield, UK
| |
Collapse
|
17
|
Meyers AFA, Bergeron M, Thakar M, Ding T, Martel A, Sandstrom P, Mahajan B, Abraham P, Kabra S, Singh N, Peter T, Ball TB. QASI: A collaboration for implementation of an independent quality assessment programme in India. Afr J Lab Med 2016; 5:442. [PMID: 28879123 PMCID: PMC5433822 DOI: 10.4102/ajlm.v5i2.442] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Accepted: 08/05/2016] [Indexed: 11/10/2022] Open
Abstract
Objective The HIV pandemic remains a significant global health concern. Accurate determination of CD4+ T-cells in patient samples relies on reliable CD4 enumeration. The Quality Assessment and Standardization programme for Immunological measures relevant to HIV/AIDS (QASI) programme of the Public Health Agency of Canada provides clinical laboratories from resource-limited countries with a mechanism to evaluate the quality of CD4 testing and develop the implementation of an independent national External Quality Assessment (EQA) programme. This study describes how QASI helped develop the capacity for managing a sustainable national CD4 EQA programme in India. Design Supported by the Public Health Agency of Canada and Clinton Foundation HIV/AIDS Initiative, QASI engaged with the National AIDS Control Organization and the Indian National AIDS Research Institute to assist in technology transfer in preparation for the implementation/management of an independent CD4 EQA programme. Technology transfer training was provided to support corrective actions and to improve the quality of CD4 testing. Inter-laboratory variation of EQA surveys between pre- and post-skill development was compared. Results Prior to training, coefficient of variation values were 14.7% (mid-level CD4 count controls) and 39.0% (low-level). Following training, variation was reduced to 10.3% for mid-level controls and 20.0% for low-level controls. Conclusion This training assisted the National AIDS Control Organization and the Indian National AIDS Research Institute in identifying the information necessary for management of an EQA programme, and developed the foundation for India to provide corrective actions for sites with challenges in achieving reliable results for CD4 enumeration. This led to a demonstrable improvement in CD4 testing quality and illustrates how country-specific training significantly improved CD4 enumeration performance for better clinical management of HIV care in India.
Collapse
Affiliation(s)
- Adrienne F A Meyers
- National HIV & Retrovirology Laboratories, Public Health Agency of Canada, JC Wilt Infectious Diseases Research Centre, Winnipeg, Canada.,Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.,Department of Medical Microbiology, University of Nairobi, Kenya
| | - Michèle Bergeron
- National HIV & Retrovirology Laboratories, Public Health Agency of Canada, JC Wilt Infectious Diseases Research Centre, Winnipeg, Canada
| | | | - Tao Ding
- National HIV & Retrovirology Laboratories, Public Health Agency of Canada, JC Wilt Infectious Diseases Research Centre, Winnipeg, Canada
| | - Alexandre Martel
- National HIV & Retrovirology Laboratories, Public Health Agency of Canada, JC Wilt Infectious Diseases Research Centre, Winnipeg, Canada
| | - Paul Sandstrom
- National HIV & Retrovirology Laboratories, Public Health Agency of Canada, JC Wilt Infectious Diseases Research Centre, Winnipeg, Canada.,Department of Medical Microbiology, University of Nairobi, Kenya
| | | | | | - Sandhya Kabra
- National AIDS Control Organization, New Delhi, India
| | - Namita Singh
- Clinton Foundation's HIV/AIDS Initiative, Botswana
| | - Trevor Peter
- Clinton Foundation's HIV/AIDS Initiative, Botswana
| | - Terry B Ball
- National HIV & Retrovirology Laboratories, Public Health Agency of Canada, JC Wilt Infectious Diseases Research Centre, Winnipeg, Canada.,Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.,Department of Medical Microbiology, University of Nairobi, Kenya.,Department of Immunology, University of Manitoba, Winnipeg, Canada
| |
Collapse
|
18
|
Kestens L, Mandy F. Thirty-five years of CD4 T-cell counting in HIV infection: From flow cytometry in the lab to point-of-care testing in the field. CYTOMETRY PART B-CLINICAL CYTOMETRY 2016; 92:437-444. [PMID: 27406947 DOI: 10.1002/cyto.b.21400] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Revised: 06/29/2016] [Accepted: 07/07/2016] [Indexed: 11/10/2022]
Abstract
CD4 T-cell counting was introduced in clinical laboratories shortly after the discovery of the human immune deficiency virus (HIV) in the early eighties. In western clinical laboratories, improvements in the CD4 T-cell counting methods were mainly driven by progress in the field of flow cytometry and immunology. In contrast, the development of dedicated CD4 T-cell counting technologies were needs driven. When antiretroviral treatment (ART) was made available on a large scale by international Acquired Immune Deficiency Syndrome (AIDS) relief programs to HIV+ patients living in low income countries in 2003, there was a distinct need for simplified and affordable CD4 T-cell counting technologies. The first decade of 2000, several compact flow cytometers appeared on the market, mainly to the benefit of low income countries with limited resources. More recently, however, portable point-of-care (POC) CD4 T-cell counting devices have been developed especially to improve access to affordable monitoring of HIV+ patients in low income countries. The accuracy of these POC instruments is not yet very well documented as many are still under development and clinical validation but preliminary evidence is encouraging. The new HIV treatment guidelines released by the World Health Organization in 2016 give CD4 T-cell counting a less central role in the management of HIV infection. It is, therefore, to be expected that CD4 T-cell counting will be phased out as a tool to assess eligibility of HIV+ patients for ART in the future. However, CD4 T-cell counting will remain a valuable tool for directing treatment against opportunistic infections. © 2016 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- L Kestens
- Immunology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.,Department of Biomedical Sciences University of Antwerp, Belgium
| | - F Mandy
- African Institute of Mathematical Sciences, Mbour, Senegal
| |
Collapse
|
19
|
Coetzee LM, Moodley K, Glencross DK. Performance Evaluation of the Becton Dickinson FACSPresto™ Near-Patient CD4 Instrument in a Laboratory and Typical Field Clinic Setting in South Africa. PLoS One 2016; 11:e0156266. [PMID: 27224025 PMCID: PMC4880207 DOI: 10.1371/journal.pone.0156266] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 05/11/2016] [Indexed: 12/27/2022] Open
Abstract
Background The BD-FACSPresto™ CD4 is a new, point-of-care (POC) instrument utilising finger-stick capillary blood sampling. This study evaluated its performance against predicate CD4 testing in South Africa. Methods Phase-I testing: HIV+ patient samples (n = 214) were analysed on the Presto™ under ideal laboratory conditions using venous blood. During Phase-II, 135 patients were capillary-bled for CD4 testing on FACSPresto™, performed according to manufacturer instruction. Comparative statistical analyses against predicate PLG/CD4 method and industry standards were done using GraphPad Prism 6. It included Bland-Altman with 95% limits of agreement (LOA) and percentage similarity with coefficient of variation (%CV) analyses for absolute CD4 count (cells/μl) and CD4 percentage of lymphocytes (CD4%). Results In Phase-I, 179/217 samples yielded reportable results with Presto™ using venous blood filled cartridges. Compared to predicate, a mean bias of 40.4±45.8 (LOA of -49.2 to 130.2) and %similarity (%CV) of 106.1%±7.75 (7.3%) was noted for CD4 absolute counts. In Phase-2 field study, 118/135 capillary-bled Presto™ samples resulted CD4 parameters. Compared to predicate, a mean bias of 50.2±92.8 (LOA of -131.7 to 232) with %similarity (%CV) 105%±10.8 (10.3%), and 2.87±2.7 (LOA of -8.2 to 2.5) with similarity of 94.7±6.5% (6.83%) noted for absolute CD4 and CD4% respectively. No significant clinical differences were indicated for either parameter using two sampling methods. Conclusion The Presto™ produced remarkable precision to predicate methods, irrespective of venous or capillary blood sampling. A consistent, clinically insignificant over-estimation (5–7%) of counts against PLG/CD4 and equivalency to FACSCount™ was noted. Further field studies are awaited to confirm longer-term use.
Collapse
Affiliation(s)
- Lindi-Marie Coetzee
- National Health Laboratory Service of South Africa (NHLS), Charlotte Maxeke Hospital, CD4 Laboratory, Parktown, Johannesburg, South Africa.,Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, 2198, Johannesburg, South Africa
| | - Keshendree Moodley
- Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, 2198, Johannesburg, South Africa
| | - Deborah Kim Glencross
- National Health Laboratory Service of South Africa (NHLS), Charlotte Maxeke Hospital, CD4 Laboratory, Parktown, Johannesburg, South Africa.,Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, 2198, Johannesburg, South Africa
| |
Collapse
|
20
|
Louis FJ, Osborne AJ, Elias VJ, Buteau J, Boncy J, Elong A, Dismer A, Sasi V, Domercant JW, Lauture D, Balajee SA, Marston BJ. Specimen Referral Network to Rapidly Scale-Up CD4 Testing: The Hub and Spoke Model for Haiti. ACTA ACUST UNITED AC 2015; 6. [PMID: 26900489 DOI: 10.4172/2155-6113.1000488] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Regular and quality CD4 testing is essential to monitor disease progression in people living with HIV. In Haiti, most laboratories have limited infrastructure and financial resources and have relied on manual laboratory techniques. We report the successful implementation of a national specimen referral network to rapidly increase patient coverage with quality CD4 testing while at the same time building infrastructure for referral of additional sample types over time. METHOD Following a thorough baseline analysis of facilities, expected workload, patient volumes, cost of technology and infrastructure constraints at health institutions providing care to HIV patients, the Haitian National Public Health Laboratory designed and implemented a national specimen referral network. The specimen referral network was scaled up in a step-wise manner from July 2011 to July 2014. RESULTS Fourteen hubs serving a total of 67 healthcare facilities have been launched; in addition, 10 healthcare facilities operate FACSCount machines, 21 laboratories operate PIMA machines, and 11 healthcare facilities are still using manual CD4 tests. The number of health institutions able to access automated CD4 testing has increased from 27 to 113 (315%). Testing volume increased 76% on average. The number of patients enrolled on ART at the first healthcare facilities to join the network increased 182% within 6 months following linkage to the network. Performance on external quality assessment was acceptable at all 14 hubs. CONCLUSION A specimen referral network has enabled rapid uptake of quality CD4 testing, and served as a backbone to allow for other future tests to be scaled-up in a similar way.
Collapse
Affiliation(s)
| | | | - Viala Jean Elias
- Laboratoire National de Santé Publique, Ministry of Health, Government of Haiti, Port-au-Prince, Haiti
| | - Josiane Buteau
- Laboratoire National de Santé Publique, Ministry of Health, Government of Haiti, Port-au-Prince, Haiti
| | - Jacques Boncy
- Laboratoire National de Santé Publique, Ministry of Health, Government of Haiti, Port-au-Prince, Haiti
| | - Angela Elong
- Partnership for Supply Chain Management, Port-au-Prince, Haiti
| | - Amber Dismer
- Centers for Diseases Control and Prevention, Atlanta, Georgia, USA
| | - Vikram Sasi
- Laboratoire National de Santé Publique, Ministry of Health, Government of Haiti, Port-au-Prince, Haiti
| | | | - Daniel Lauture
- Unite de Gestion des Programmes, Ministry of Health, Government of Haiti, Port-au-Prince, Haiti
| | | | | |
Collapse
|
21
|
Fajardo E, Metcalf C, Piriou E, Gueguen M, Maman D, Chaillet P, Cox V, Rumaney MB, Tunggal S, Kosack C, Roberts T. Errors generated by a point-of-care CD4+ T-lymphocyte analyser: a retrospective observational study in nine countries. Bull World Health Organ 2015; 93:623-30. [PMID: 26478626 PMCID: PMC4581638 DOI: 10.2471/blt.14.146480] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2014] [Revised: 05/14/2015] [Accepted: 05/21/2015] [Indexed: 12/29/2022] Open
Abstract
OBJECTIVE To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by Médecins Sans Frontières (MSF) in field projects and identify factors associated with invalid results. METHODS We collated 25,616 CD4+ T-lymphocyte test results from 39 sites in nine countries for the years 2011 to 2013. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire. The analyser performs a series of checks to ensure that all steps of the analysis are completed successfully; if not, an invalid result is reported. We calculated the proportion of invalid results by device and by operator. Regression analyses were used to investigate factors associated with invalid results. FINDINGS There were 3354 invalid test results (13.1%) across 39 sites, for 58 Alere PimaTM devices and 180 operators. The median proportion of errors per device and operator was 12.7% (interquartile range, IQR: 10.3-19.9) and 12.1% (IQR: 7.1-19.2), respectively. The proportion of invalid results varied widely by country, setting, user and device. Errors were not associated with settings, user experience or the number of users per device. Tests performed on capillary blood samples were significantly less likely to generate errors compared to venous whole blood. CONCLUSION The Alere Pima CD4+ analyser generated a high proportion of invalid test results, across different countries, settings and users. Most error codes could be attributed to the operator, but the exact causes proved difficult to identify. Invalid results need to be factored into the implementation and operational costs of routine CD4+ T-lymphocyte testing.
Collapse
Affiliation(s)
- Emmanuel Fajardo
- Médecins Sans Frontières (MSF), Southern Africa Medical Unit (SAMU), Waverly Business Park, 303 A&B, Cape Town, South Africa
| | - Carol Metcalf
- Médecins Sans Frontières (MSF), Southern Africa Medical Unit (SAMU), Waverly Business Park, 303 A&B, Cape Town, South Africa
| | | | | | | | | | | | - Maryam B Rumaney
- Médecins Sans Frontières (MSF), Southern Africa Medical Unit (SAMU), Waverly Business Park, 303 A&B, Cape Town, South Africa
| | | | - Cara Kosack
- MSF, Diagnostic Network, Amsterdam, Netherlands
| | | |
Collapse
|
22
|
Estimating implementation and operational costs of an integrated tiered CD4 service including laboratory and point of care testing in a remote health district in South Africa. PLoS One 2014; 9:e115420. [PMID: 25517412 PMCID: PMC4269438 DOI: 10.1371/journal.pone.0115420] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 11/23/2014] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND An integrated tiered service delivery model (ITSDM) has been proposed to provide 'full-coverage' of CD4 services throughout South Africa. Five tiers are described, defined by testing volumes and number of referring health-facilities. These include: (1) Tier-1/decentralized point-of-care service (POC) in a single site; Tier-2/POC-hub servicing processing < 30-40 samples from 8-10 health-clinics; Tier-3/Community laboratories servicing ∼ 50 health-clinics, processing < 150 samples/day; high-volume centralized laboratories (Tier-4 and Tier-5) processing < 300 or > 600 samples/day and serving > 100 or > 200 health-clinics, respectively. The objective of this study was to establish costs of existing and ITSDM-tiers 1, 2 and 3 in a remote, under-serviced district in South Africa. METHODS Historical health-facility workload volumes from the Pixley-ka-Seme district, and the total volumes of CD4 tests performed by the adjacent district referral CD4 laboratories, linked to locations of all referring clinics and related laboratory-to-result turn-around time (LTR-TAT) data, were extracted from the NHLS Corporate-Data-Warehouse for the period April-2012 to March-2013. Tiers were costed separately (as a cost-per-result) including equipment, staffing, reagents and test consumable costs. A one-way sensitivity analyses provided for changes in reagent price, test volumes and personnel time. RESULTS The lowest cost-per-result was noted for the existing laboratory-based Tiers- 4 and 5 ($6.24 and $5.37 respectively), but with related increased LTR-TAT of > 24-48 hours. Full service coverage with TAT < 6-hours could be achieved with placement of twenty-seven Tier-1/POC or eight Tier-2/POC-hubs, at a cost-per-result of $32.32 and $15.88 respectively. A single district Tier-3 laboratory also ensured 'full service coverage' and < 24 hour LTR-TAT for the district at $7.42 per-test. CONCLUSION Implementing a single Tier-3/community laboratory to extend and improve delivery of services in Pixley-ka-Seme, with an estimated local ∼ 12-24-hour LTR-TAT, is ∼ $2 more than existing referred services per-test, but 2-4 fold cheaper than implementing eight Tier-2/POC-hubs or providing twenty-seven Tier-1/POCT CD4 services.
Collapse
|
23
|
Compatibility of stabilized whole blood products with CD4 technologies and their suitability for quality assessment programs. PLoS One 2014; 9:e103391. [PMID: 25105290 PMCID: PMC4126665 DOI: 10.1371/journal.pone.0103391] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 07/01/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND CD4 T cell enumeration is the most widely used prognostic marker for management of HIV disease. Internal quality control and external quality assessment (EQA) programs are critical to ensure reliability of clinical measurements. The utility of stabilized whole blood products (SWBP) as a test reagent for EQA programs such as Quality Assessment and Standardization for Immunological measures relevant to HIV/AIDS (QASI) program have been demonstrated previously. Since then, several new commercial SWBPs and alternative CD4 enumeration technologies have become available. Seven SWBPs were evaluated on seven different enumeration platforms to determine which product(s) are most suitable for EQA programs that support multiple analytical technologies. METHOD Assessment of SWBPs was based on two criteria: (1) accuracy of CD4 T cell measurements and; (2) stability under sub optimal storage conditions. RESULTS Three SWBPs (Multi-Check, StatusFlow and CD4 Count) showed accurate CD4 T-cell absolute count and percentage values across six of the enumeration platforms. All products retain stability up to 18 days at 21-23°C with the exception of Multi-Check-high on FacsCount and Multi-Check-Low and StatusFlow-Low on Pima. One of the products (CD4 Count) retained stability for three days on all platforms tested when stored at 37°C. CONCLUSION This study demonstrated that the characteristics of commercially available SWBPs vary across multiple CD4 platforms. The compatibility of testing panels for EQA programs with multiple analytical platforms needs to be carefully considered, especially in large multiplatform CD4 EQA programs. The selection of a suitable cross-platform SWBP is an increasing challenge as more reagents and platforms are introduced for CD4 T-cell enumeration.
Collapse
|
24
|
Landis RC. Issue highlights--July 2013. CYTOMETRY PART B-CLINICAL CYTOMETRY 2014; 84:205-6. [PMID: 23788472 DOI: 10.1002/cyto.b.21100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
25
|
Impact of proficiency testing program for laboratories conducting early diagnosis of HIV-1 infection in infants in low- to middle-income countries. J Clin Microbiol 2013; 52:773-80. [PMID: 24353004 DOI: 10.1128/jcm.03097-13] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
A voluntary, cost-free external quality assessment (EQA) program established by the U.S. Centers for Disease Control and Prevention (CDC) was implemented to primarily monitor the performance of laboratories conducting HIV Early Infant Diagnosis (EID) from dried blood spots (DBS) in low- to middle-income countries since 2006. Ten blind DBS proficiency test (PT) specimens and 100 known HIV-positive and -negative DBS specimens (to be used as internal controls) were shipped triannually to participating laboratories with reports for the PT specimens due within 30 days. The participant's results and a summary of the performance of all participating laboratories and each diagnostic method were provided after each test cycle. Enrollment in the CDC PT program expanded progressively from 17 laboratories from 11 countries in 2006 to include 136 laboratories from 41 countries at the end of 2012. Despite external pressures to test and treat more children while expanding EID programs, mean PT test scores significantly improved over time as demonstrated by the upward trend from mid-2006 to the end of 2012 (P=0.001) and the increase in the percentage of laboratories scoring 100% (P=0.003). The mean test scores plateaued over the past 10 testing cycles, ranging between 98.2% and 99.7%, and discordant test results still occur but at a rate of no higher than 2.6%. Analysis of these test results suggests a positive impact of proficiency testing on the testing performance of the participating laboratories, and a continuous training program and proficiency testing participation may translate into laboratories improving their testing accuracy.
Collapse
|
26
|
Field evaluation in Chad of community usage of CD4 T lymphocyte counting by alternative single-platform flow cytometry. BMC Health Serv Res 2013; 13:373. [PMID: 24083615 PMCID: PMC3849920 DOI: 10.1186/1472-6963-13-373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Accepted: 09/27/2013] [Indexed: 11/30/2022] Open
Abstract
Background Field and community evaluation of the routine usage of CD4 T counting platforms is essential in resource-poor countries for efficient and cost-effective monitoring of HIV-infected adults and children attending health care centers. Methods We herein addressed the principal issues raised by the implementation of the single-platform, volumetric Auto40 flow cytometer (Apogee Flow Systems Ltd, Hemel Hempstead, UK) in 8 community HIV monitoring laboratories of different levels throughout Chad. This is a country with particularly difficult conditions, both in terms of climate and vast geographical territory, making the decentralization of the therapeutic management of HIV-infected patients challenging. Results The routine usage of the Auto40 flow cytometers for a period of 5 years (2008–2013) confirms the reliability and robustness of the analyzer for community-based CD4 T cell enumeration in terms of both absolute numbers and percentages to enable accurate monitoring of HIV-infected adults and children. However, our observations suggest that the Auto40 mini flow cytometer is not suitable for all laboratories as it is oversized and ultimately very expensive. Conclusion The Chad experience with the Auto40 flow cytometer suggests that its usage in resource-limited settings should be mainly reserved to reference (level 1) or district (level 2) laboratories, rather than to laboratories of health care centres (level 3).
Collapse
|
27
|
Logan C, Givens M, Ives JT, Delaney M, Lochhead MJ, Schooley RT, Benson CA. Performance evaluation of the MBio Diagnostics point-of-care CD4 counter. J Immunol Methods 2012; 387:107-13. [PMID: 23063690 DOI: 10.1016/j.jim.2012.10.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 09/28/2012] [Accepted: 10/04/2012] [Indexed: 10/27/2022]
Abstract
The measurement of the absolute CD4 T-cell count is critical in the initial evaluation and staging of HIV-infected persons, yet access to this technology remains limited in many low resource settings where disease burden is highest. Here we evaluate the performance of a prototype point-of-care device (POC) to quantify CD4 T cells from MBio Diagnostics, Inc. Whole blood samples, both venous and capillary (finger stick), were collected from known HIV-infected participants at the University of California, San Diego Antiviral Research Center, and tested using the MBio system and conventional flow cytometry. A total of 94 venipuncture and 52 capillary samples were processed and statistical analyses included comparison to flow cytometry results. For the venipuncture samples, Bland-Altman analysis resulted in a mean bias of -10 cells/μL (-23 to +3 cells/μL, 95% CI), and limits of agreement (LOA) of -132 and +112 cells/μL. For the capillary samples, Bland-Altman resulted in a mean bias of -4 cells/μL (-31 to +23 cells/μL, 95% CL), and LOA of -195 and +186 cells/μL. For the San Diego study cohort, the prototype MBio system showed negligible quantitative bias relative to flow cytometry. Higher variability was observed in the capillary samples relative to venipuncture, but system precision for both capillary and venipuncture samples was good. There was also close agreement between results from the same participant when tested with two different systems, different operators and different locations. This preliminary evaluation suggests that the MBio CD4 device holds promise as a POC system for quantitation of CD4 T cells in limited-resource settings.
Collapse
Affiliation(s)
- Cathy Logan
- Division of Infectious Diseases, University of California, 9500 Gilman Drive, MC 0711, San Diego, CA 92093, USA.
| | | | | | | | | | | | | |
Collapse
|
28
|
Larson B, Schnippel K, Ndibongo B, Long L, Fox MP, Rosen S. How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa. PLoS One 2012; 7:e35444. [PMID: 22532854 PMCID: PMC3331987 DOI: 10.1371/journal.pone.0035444] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2011] [Accepted: 03/16/2012] [Indexed: 11/26/2022] Open
Abstract
Integrating POC CD4 testing technologies into HIV counseling and testing (HCT) programs may improve post-HIV testing linkage to care and treatment. As evaluations of these technologies in program settings continue, estimates of the costs of POC CD4 tests to the service provider will be needed and estimates have begun to be reported. Without a consistent and transparent methodology, estimates of the cost per CD4 test using POC technologies are likely to be difficult to compare and may lead to erroneous conclusions about costs and cost-effectiveness. This paper provides a step-by-step approach for estimating the cost per CD4 test from a provider's perspective. As an example, the approach is applied to one specific POC technology, the Pima Analyzer. The costing approach is illustrated with data from a mobile HCT program in Gauteng Province of South Africa. For this program, the cost per test in 2010 was estimated at $23.76 (material costs = $8.70; labor cost per test = $7.33; and equipment, insurance, and daily quality control = $7.72). Labor and equipment costs can vary widely depending on how the program operates and the number of CD4 tests completed over time. Additional costs not included in the above analysis, for on-going training, supervision, and quality control, are likely to increase further the cost per test. The main contribution of this paper is to outline a methodology for estimating the costs of incorporating POC CD4 testing technologies into an HCT program. The details of the program setting matter significantly for the cost estimate, so that such details should be clearly documented to improve the consistency, transparency, and comparability of cost estimates.
Collapse
Affiliation(s)
- Bruce Larson
- Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America.
| | | | | | | | | | | |
Collapse
|
29
|
Glencross DK, Coetzee LM, Faal M, Masango M, Stevens WS, Venter WF, Osih R. Performance evaluation of the Pima™ point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc 2012; 15:3. [PMID: 22284546 PMCID: PMC3310849 DOI: 10.1186/1758-2652-15-3] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Accepted: 01/30/2012] [Indexed: 11/12/2022] Open
Abstract
Background Point-of-care CD4 testing can provide immediate CD4 reporting at HIV-testing sites. This study evaluated performance of capillary blood sampling using the point-of-care Pima™ CD4 device in representative primary health care clinics doing HIV testing. Methods Prior to testing, prescribed capillary-sampling and instrument training was undertaken by suppliers across all sites. Matching venous EDTA samples were drawn throughout for comparison to laboratory predicate methodology (PLG/CD4). In Phase I, Pima™ cartridges were pipette-filled with EDTA venous blood in the laboratory (N = 100). In Phase II (N = 77), Pima™ CD4 with capillary sampling was performed by a single operator in a hospital-based antenatal clinic. During subsequent field testing, Pima™ CD4 with capillary sampling was performed in primary health care clinics on HIV-positive patients by multiple attending nursing personnel in a rural clinic (Phase-IIIA, N = 96) and an inner-city clinic (Phase-IIIB, N = 139). Results Pima™ CD4 compared favourably to predicate/CD4 when cartridges were pipette-filled with venous blood (bias -17.3 ± STDev = 36.7 cells/mm3; precision-to-predicate %CV < 6%). Decreased precision of Pima™ CD4 to predicate/CD4 (varying from 17.6 to 28.8%SIM CV; mean bias = 37.9 ± STDev = 179.5 cells/mm3) was noted during field testing in the hospital antenatal clinic. In the rural clinic field-studies, unacceptable precision-to-predicate and positive bias was noted (mean 28.4%SIM CV; mean bias = +105.7 ± STDev = 225.4 cells/mm3). With additional proactive manufacturer support, reliable performance was noted in the subsequent inner-city clinic field study where acceptable precision-to-predicate (11%SIM CV) and less bias of Pima™ to predicate was shown (BA bias ~11 ± STDev = 69 cells/mm3). Conclusions Variable precision of Pima™ to predicate CD4 across study sites was attributable to variable capillary sampling. Poor precision was noted in the outlying primary health care clinic where the system is most likely to be used. Stringent attention to capillary blood collection technique is therefore imperative if technologies like Pima™ are used with capillary sampling at the POC. Pima™ CD4 analysis with venous blood was shown to be reproducible, but testing at the point of care exposes operators to biohazard risk related to uncapping vacutainer samples and pipetting of blood, and is best placed in smaller laboratories using established principles of Good Clinical Laboratory Practice. The development of capillary sampling quality control methods that assure reliable CD4 counts at the point of care are awaited.
Collapse
Affiliation(s)
- Deborah K Glencross
- Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, 2198, Johannesburg, South Africa.
| | | | | | | | | | | | | |
Collapse
|
30
|
Frean J, Perovic O, Fensham V, McCarthy K, von Gottberg A, de Gouveia L, Poonsamy B, Dini L, Rossouw J, Keddy K, Alemu W, Yahaya A, Pierson A, Dolmazon V, Cognat S, Ndihokubwayo JB. External quality assessment of national public health laboratories in Africa, 2002-2009. Bull World Health Organ 2012; 90:191-199A. [PMID: 22461714 DOI: 10.2471/blt.11.091876] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Revised: 10/28/2011] [Accepted: 11/09/2011] [Indexed: 10/28/2022] Open
Abstract
OBJECTIVE To describe findings from an external quality assessment programme involving laboratories in Africa that routinely investigate epidemic-prone diseases. METHODS Beginning in 2002, the Regional Office for Africa of the World Health Organization (WHO) invited national public health laboratories and related facilities in Africa to participate in the programme. Three surveys comprising specimens and questionnaires associated with bacterial enteric diseases, bacterial meningitis, plague, tuberculosis and malaria were sent annually to test participants' diagnostic proficiency. Identical surveys were sent to referee laboratories for quality control. Materials were prepared, packaged and shipped in accordance with standard protocols. Findings and reports were due within 30 days. Key methodological decisions and test results were categorized as acceptable or unacceptable on the basis of consensus feedback from referees, using established grading schemes. FINDINGS Between 2002 and 2009, participation increased from 30 to 48 Member States of the WHO and from 39 to 78 laboratories. Each survey was returned by 64-93% of participants. Mean turnaround time was 25.9 days. For bacterial enteric diseases and meningitis components, bacterial identification was acceptable in 65% and 69% of challenges, respectively, but serotyping and antibiotic susceptibility testing and reporting were frequently unacceptable. Microscopy was acceptable for 73% of plague challenges. Tuberculosis microscopy was satisfactorily performed, with 87% of responses receiving acceptable scores. In the malaria component, 82% of responses received acceptable scores for species identification but only 51% of parasite quantitation scores were acceptable. CONCLUSION The external quality assessment programme consistently identified certain functional deficiencies requiring strengthening that were present in African public health microbiology laboratories.
Collapse
Affiliation(s)
- John Frean
- National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Providing Immediate CD4 Count Results at HIV Testing Improves ART Initiation. J Acquir Immune Defic Syndr 2011; 58:e54-9. [DOI: 10.1097/qai.0b013e3182303921] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa. J Clin Microbiol 2011; 49:4356-60. [PMID: 21976767 DOI: 10.1128/jcm.05167-11] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Implementation of Xpert MTB/RIF requires quality assessment. A pilot program using dried culture spots (DCSs) of inactivated Mycobacterium tuberculosis is described. Of 274 DCS results received, 2.19% generated errors; the remainder yielded 100% correct Mycobacterium tuberculosis detection. The probe A cycle threshold (C(T)) variability of three DCS batches was ≤ 3.47. The study of longer-term DCS stability is ongoing.
Collapse
|
33
|
Dieye TN, Diaw PA, Daneau G, Wade D, Sylla Niang M, Camara M, Diallo AA, Toure Kane C, Diop Ndiaye H, Mbengue B, Dieye A, Kestens L, Mboup S. Evaluation of a flow cytometry method for CD4 T cell enumeration based on volumetric primary CD4 gating using thermoresistant reagents. J Immunol Methods 2011; 372:7-13. [PMID: 21835181 DOI: 10.1016/j.jim.2011.07.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2010] [Revised: 07/08/2011] [Accepted: 07/11/2011] [Indexed: 10/17/2022]
Abstract
Laboratory follow-up of HIV patients in resource-limited settings requires appropriate instruments for CD4 T cell enumeration. In this study, we evaluated the application of a simplified, mobile and robust flow cytometry system, the Apogee Auto 40 analyzer (Auto40) using thermoresistant reagents, for CD4 T cell enumeration. We measured the absolute CD4 counts in fresh whole blood samples from 170 Senegalese subjects, including 129 HIV-positive (HIV+) patients and 41 HIV-negative (HIV-) controls. Based on volumetric primary CD4 gating, cells were stained with commercially available reagents (Easy MoAb CD4;Bio-D, Valenzano, Italy) and analyzed on the Auto40. The results were compared with those from the FACSCount system (Becton Dickinson, San Jose, USA). Repeatability analysis was performed on duplicate testing of 49 samples on both FACSCount and Auto40. The intra-run precision was measured by 10 replicates using 3 clinical blood samples with low, intermediate and high CD4 concentrations. The results from the two instruments were in good agreement. The percent similarity between the results of both instruments was 99%±relative standard deviation of 12.7%. The concordance correlation coefficient was 0.99. The absolute bias and limits of agreement (LOA) between the two instruments, calculated by Bland-Altman analysis, were clinically acceptable (bias: +4 cells/μl; LOA: -111 to +120 cells/μl). The clinical agreement between the two instruments at a cutoff of 200 CD4 cells/μl was 94%. The repeatability of measurements on the Auto40 was also similar to that observed with FACSCount system (bias +0.1 cells/μl, coefficient of variation 2.5% vs bias -1.1cells/μl, coefficient of variation 2.9% respectively). In conclusion, our results indicate that the Auto 40 system, using thermoresistant reagents, is suitable for CD4 T cell enumeration and will be a helpful tool to improve HIV laboratory monitoring in resource-limited settings.
Collapse
Affiliation(s)
- Tandakha Ndiaye Dieye
- Immunology Unit, Laboratory of Bacteriology-Virology, CHU Le Dantec University Teaching Hospital, BP 7325 Dakar, Senegal.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Lawrie D, Coetzee LM, Glencross DK. A model for continuous quality control incorporating sample-to-sample assessment of optical alignment, fluorescence sensitivity, and volumetric operation of flow cytometers. CYTOMETRY PART B-CLINICAL CYTOMETRY 2010; 78:201-10. [PMID: 20419764 DOI: 10.1002/cyto.b.20520] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Bead count rate (BCR) monitoring successfully identifies pipetting error during single platform CD4 enumeration. Despite rigorous prescribed quality control performed, preliminary data suggested that BCR outliers could also be attributed to occasional failure of flow cytometric volumetric operation. The aim of this report was to use counting beads in a model of continuous quality control (CQC) to monitor overall flow cytometric performance (laser alignment, fluorescence stability and volumetric operation). METHODS The proposed CQC model used FlowCheck and IMMUNOTROL blood controls daily. Extended monitoring of fluidics (FPV; beads and sheath only) and sample preparation (SPV; blood, IMMUNOPREP and beads) was done daily on five flow cytometers over five consecutive days prior to testing patient samples. Sample-to-sample CQC included monitoring BCR, selected time/fluorescence histograms (Time vs. Count; Time vs. Fluorescence and Forward Scatter vs. Fluorescence) and full peak coefficient of variation (FPCV) for 2000 samples tested. RESULTS Prescribed quality controls showed Half Peak CV values of <2% (FlowCheck) with Immunotrol within 0.5SD of the target means. Laser stability was confirmed (FPCV values <2%). However, fluidics (volumetric operation) fluctuated as indicated by a 3.2% BCR outlier rate of 2,000 samples tested (minus pipetting error) despite optimal fluidics performance verified at start-up (FPV CV < 3%). CONCLUSIONS Sustained laser stability was confirmed with Time vs. Fluorescence histograms, but Time vs. Count histograms were insufficient to detect intermittent volumetric failure. The proposed CQC model, incorporating BCR monitoring with time/fluorescence histograms and FPCV monitoring can identify all volumetric inconsistencies in real-time.
Collapse
Affiliation(s)
- Denise Lawrie
- National Health Laboratory Services and Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa
| | | | | |
Collapse
|
35
|
Westerman LE, Kohatsu L, Ortiz A, McClain B, Kaplan J, Spira T, Marston B, Jani IV, Nkengasong J, Parsons LM. A quality management systems approach for CD4 testing in resource-poor settings. Am J Clin Pathol 2010; 134:556-67. [PMID: 20855636 DOI: 10.1309/ajcpp7mchfylx2fm] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Quality assurance (QA) is a systematic process to monitor and improve clinical laboratory practices. The fundamental components of a laboratory QA program include providing a functional and safe laboratory environment, trained and competent personnel, maintained equipment, adequate supplies and reagents, testing of appropriate specimens, internal monitoring of quality, accurate reporting, and external quality assessments. These components are necessary to provide accurate and precise CD4 T-cell counts, an essential test to evaluate start of and monitor effectiveness of antiretroviral therapy for HIV-infected patients. In recent years, CD4 testing has expanded dramatically in resource-limited settings. Information on a CD4 QA program as described in this article will provide guidelines not only for clinical laboratory staff but also for managers of programs responsible for supporting CD4 testing. All agencies involved in implementing CD4 testing must understand the needs of the laboratory and provide advocacy, guidance, and financial support to established CD4 testing sites and programs. This article describes and explains the procedures that must be put in place to provide reliable CD4 determinations in a variety of settings.
Collapse
|
36
|
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258-68. [PMID: 20404739 DOI: 10.1097/qai.0b013e3181d0db97] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND As second-line antiretroviral therapy (ART) availability increases in resource-limited settings, questions about the value of laboratory monitoring remain. We assessed the outcomes and cost-effectiveness (CE) of laboratory monitoring to guide switching ART. METHODS We used a computer model to project life expectancy and costs of different strategies to guide ART switching in patients in Côte d'Ivoire. Strategies included clinical assessment, CD4 count, and HIV RNA testing. Data were from clinical trials and cohort studies from Côte d'Ivoire and the literature. Outcomes were compared using the incremental CE ratio. We conducted multiple sensitivity analyses to assess uncertainty in model parameters. RESULTS Compared with first-line ART only, second-line ART increased life expectancy by 24% with clinical monitoring only, 46% with CD4 monitoring, and 61% with HIV RNA monitoring. The incremental CE ratio of switching based on clinical monitoring was $1670 per year of life gained (YLS) compared with first-line ART only; biannual CD4 monitoring was $2120 per YLS. The CE ratio of biannual HIV RNA testing ranged from $2920 ($87/test) to $1990 per YLS ($25/test). If second-line ART costs were reduced, the CE of HIV RNA monitoring improved. CONCLUSIONS In resource-limited settings, CD4 count and HIV RNA monitoring to guide switching to second-line ART improve survival and, under most conditions, are cost-effective.
Collapse
|
37
|
Janossy G, Mandy F. Translational medicine as implementation science in the field of monitoring HIV and TB. New concepts emanating from resource-poor countries. CYTOMETRY PART B-CLINICAL CYTOMETRY 2010; 78:183-7. [DOI: 10.1002/cyto.b.20527] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
38
|
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret A, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife K, deBruyn G, Gray G, McIntyre J, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Coombs RW, Morrow R, Whittington W, Corey L, Wald A, Celum C. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One 2009; 4:e5272. [PMID: 19404392 PMCID: PMC2671170 DOI: 10.1371/journal.pone.0005272] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2009] [Accepted: 03/19/2009] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort. METHODS HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4 count >or=250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa. Demographic, behavioral, clinical and laboratory characteristics were assessed. RESULTS Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had cohabitated for a median of 5 years (range 2-9) with 28% reporting unprotected sex in the month prior to enrollment. Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-diagnosed sexually transmitted infections were uncommon (<5%), except for Trichomonas vaginalis in 14% of HIV-1 infected women. Median baseline CD4 count for HIV-1 infected participants was 462cells/mcL and median HIV-1 plasma RNA was 4.2 log(10) copies/mL. After adjusting for age and African region, correlates of HIV-1 RNA level included male gender (+0.24 log(10) copies/mL; p<0.001) and CD4 count (-0.25 and -0.55 log(10) copies/mL for CD4 350-499 and >500 relative to <350, respectively, p<0.001). CONCLUSIONS The Partners Study successfully enrolled a cohort of 3408 heterosexual HIV-1 serodiscordant couples in Africa at high risk for HIV-1 transmission. Follow-up of this cohort will evaluate the efficacy of acyclovir for HSV-2 suppression in preventing HIV-1 transmission and provide insights into biological and behavioral factors determining heterosexual HIV-1 transmission. TRIAL REGISTRATION ClinicalTrials.gov NCT00194519.
Collapse
Affiliation(s)
- Jairam R. Lingappa
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Pediatrics, University of Washington, Seattle, Washington, United States of America
| | - Erin Kahle
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
| | - Nelly Mugo
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
- Department of Obstetrics & Gynecology, University of Nairobi & Kenyatta National Hospital, Nairobi, Kenya
| | - Andrew Mujugira
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
| | - Amalia Magaret
- Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
- Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Institute, Seattle, Washington, United States of America
| | - Jared Baeten
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Elizabeth A. Bukusi
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
- Department of Obstetrics & Gynecology, University of Nairobi & Kenyatta National Hospital, Nairobi, Kenya
- Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Craig R. Cohen
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California, United States of America
| | - Elly Katabira
- Infectious Disease Institute, Makerere University, Kampala, Uganda
| | - Allan Ronald
- University of Manitoba, Winnipeg, Manitoba, Canada
| | - James Kiarie
- Department of Obstetrics & Gynecology, University of Nairobi & Kenyatta National Hospital, Nairobi, Kenya
| | - Carey Farquhar
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Epidemiology, University of Washington, Seattle, Washington, United States of America
| | - Grace John Stewart
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | | | - M. Essex
- Department of Immunology & Infectious Diseases, Harvard School of Public Health, Harvard University, Boston, Massachusetts, United States of America
| | - Edwin Were
- Department of Reproductive Health, Moi University, Eldoret, Kenya
| | - Kenneth Fife
- Department of Medicine, Indiana University, Indianapolis, Indiana, United States of America
| | - Guy deBruyn
- Perinatal HIV Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa
| | - Glenda Gray
- Perinatal HIV Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa
| | - James McIntyre
- Perinatal HIV Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa
| | | | - Saidi Kapiga
- Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- Department of Epidemiology & Population Health, London School of Hygiene and Tropical Medicine, London, England
| | - David Coetzee
- Infectious Disease Epidemiology Unit, University of Cape Town, Cape Town, Republic of South Africa
| | - Susan Allen
- Rwanda-Zambia HIV Research Group (RZHRG) and Emory University, Rollins School of Public Health, Atlanta, Georgia, United States of America
| | | | | | - Etienne Karita
- Rwanda-Zambia HIV Research Group (RZHRG), Kigali, Rwanda
| | | | - Sinead Delany
- Reproductive Health & HIV Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa
| | - Helen Rees
- Reproductive Health & HIV Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa
| | | | - Robert W. Coombs
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
| | - Rhoda Morrow
- Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
| | - William Whittington
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Lawrence Corey
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
- Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Institute, Seattle, Washington, United States of America
| | - Anna Wald
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
- Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Institute, Seattle, Washington, United States of America
- Department of Epidemiology, University of Washington, Seattle, Washington, United States of America
| | - Connie Celum
- Department of Global Health, University of Washington, Seattle, Washington, United States of America
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Epidemiology, University of Washington, Seattle, Washington, United States of America
| | | |
Collapse
|
39
|
Stevens W, Gelman R, Glencross DK, Scott LE, Crowe SM, Spira T. Evaluating new CD4 enumeration technologies for resource-constrained countries. Nat Rev Microbiol 2008; 6:S29-38. [PMID: 22745957 DOI: 10.1038/nrmicro2000] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
40
|
Denny TN, Gelman R, Bergeron M, Landay A, Lam L, Louzao R, Mandy FF, Schmitz J, Spira T, Wilkening C, Glencross DK. A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study. CYTOMETRY PART B-CLINICAL CYTOMETRY 2008; 74 Suppl 1:S52-64. [PMID: 18351622 DOI: 10.1002/cyto.b.20417] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND The global HIV/AIDS pandemic and guidelines for initiating anti-retroviral therapy (ART) and opportunistic infection prophylaxis demand affordable, reliable, and accurate CD4 testing. A simple innovative approach applicable to existing technology that has been successfully applied in resource-challenged settings, PanLeukogated CD4 (PLG), could offer solutions for cost saving and improved precision. METHODS Day-old whole blood from 99 HIV+ donors was simultaneously studied in five North-American laboratories to compare the performance of their predicate methods with the dual-platform PLG method. The predicate technology included varying 4-color CD45/CD3/CD4/CD8 protocols on different flow cytometers. Each laboratory also assayed eight replicate specimens of day-old blood from 10 to 14 local donors. Bias and precision of predicate and PLG methods was studied between- and within-participating laboratories. RESULTS Significantly (P < 0.0001) improved between-laboratory precision/coefficient of variation (CV%) was noted using the PLG method (overall median 9.3% vs. predicate median CV 13.1%). Within-laboratory precision was also significantly (P < 0.0001) better overall using PLG (median 4.6% vs. predicate median CV 6.2%) and in 3 of the 5 laboratories. PLG counts tended to be 11% smaller than predicate methods (P < 0.0001) for shipped (median of predicate-PLG = 31) and local specimens (median of predicate-PLG = 23), both overall and in 4 of 5 laboratories (median decreases of 4, 16, 20, and 21% in shipped specimens); the other laboratory had a median increase of 5%. CONCLUSION Laboratories using predicate CD4 methods similar to those in this study could improve their between-laboratory and their within-laboratory precision, and reduce costs, by switching to the PLG method after adequate training, if a change (usually, a decrease) in CD4 counts is acceptable to their health systems.
Collapse
Affiliation(s)
- Thomas N Denny
- Human Vaccine Institute, Duke University Medical Center, Durham, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Glencross DK, Janossy G, Coetzee LM, Lawrie D, Scott LE, Sanne I, McIntyre JA, Stevens W. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: Findings from the first year of the CIPRA-SA cohort. CYTOMETRY PART B-CLINICAL CYTOMETRY 2008; 74 Suppl 1:S131-40. [DOI: 10.1002/cyto.b.20391] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
42
|
Mandy F, Janossy G, Bergeron M, Pilon R, Faucher S. Affordable CD4 T-cell enumeration for resource-limited regions: A status report for 2008. CYTOMETRY PART B-CLINICAL CYTOMETRY 2008; 74 Suppl 1:S27-39. [DOI: 10.1002/cyto.b.20414] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|